) --Investors, get ready for a very busy week of biotech and pharmaceutical earnings and FDA drug decision approvals.
Monday, July 23
will announce second-quarter financial results before the opening bell. Investors will be focused on sales of Esbriet, which InterMune is selling in Europe as a treatment for the serious lung disease idiopathic pulmonary fibrosis. The consensus sales estimate for Esbriet in the June quarter is $7.8 million.
Also watch for what InterMune says about new patient starts on Esbriet in the quarter. First quarter new-patient adds dipped to 363 in the first quarter from 402 in the fourth quarter 2011. Given the new, more favorable reimbursement opinion in Germany, new patients on Esbriet should have rebounded and started to grow again in the June quarter.
InterMune is expected to lose 28 cents a share on total revenue of $36.35 million in the second quarter.
( AMLN) and
Human Genome Sciences
( HGSI) also report second-quarter results on Monday but are less important given the in-process acquisitions by
Tuesday, July 24
earnings on tap, with current consensus pegged at earnings of $1.56 per share on total revenue of $1.33 billion for the June quarter.
Drilling deeper in Biogen June earnings, worldwide sales of the multiple sclerosis drug Tysabri are expected to total $415 million, with between 140 to 150 new patients starts per week in the quarter. Consensus sales estimate for Avonex, the company's other multiple sclerosis drug, is $428 million in the U.S. and $269 million ex-U.S.
reports second-quarter earnings, with analysts on average expected 63 cents per share on total revenue of $108.9 million.
Wednesday, July 25
reports June quarter results, look for earnings of 37 cents per share on total revenue (Soliris sales) of $263 million.
second-quarter earnings: Consensus 25 cents per share on $255.9 million.
Also reporting Wednesday are Bristol-Myers Squibb,
Thursday July 26
The biggest day of the week, headlined by two FDA drug approval decisions:
prescription fish-oil pill Vascepa and
Lodotra, a long-acting formulation of the common steroid prednisone intended for rheumatoid arthritis pain relief.
Thursday is also the busiest biotech earnings days of the week, with
all reporting second-quarter results.
Amgen: Analysts are looking for earnings of $1.54 per share on total revenue of $4.08 billion. Worldwide Aranesp sales are expected to total $525 million in the quarter, Prolia/Xgeva sales $279 million, Enbrel sales $962 million.
Celgene: Consensus earnings of $1.18 per share on total revenue of $1.35 billion, including Revlimid sales of $922 million.
Gilead Sciences: Consensus earnings of 95 cents per share on total revenue of $2.29 billion, encompassing total product sales of $2.2 billion and worldwide HIV franchise sales of $1.88 billion.
Alkermes: Consensus earnings estimate of 16 cents per share on total revenue of $127.5 million.
United Therapeutics: Consensus earnings estimate of $1.13 per share on total revenue of $213.7 million.
Also reporting second-quarter earnings on Thursday:
Friday, July 27
reports second-quarter earnings.
: FDA approval decision for expansion of the Relistor label to include treatment of opioid-induced constipation in patients with chronic, non-cancer pain.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.